Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01726985 · ClinicalTrials.gov registry record

Model for Heart Failure ExAcerbation Reduction Trial

A clinical trial, sponsored by Cleveland Clinic Florida.

Completed
Registry status
230
Enrollment target

NCT01726985 is a clinical trial that has completed, run by Cleveland Clinic Florida. The registered enrollment target is 230 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01726985 has completed, sponsored by Cleveland Clinic Florida.

COMPLETED
Registry status
230 participants
Enrollment target

Study Summary

Heart failure is the leading cause of hospitalizations and readmissions in the United States and is a tremendous economic strain on our healthcare system. There is currently, based on national averages, a 30% readmission rate and 10% mortality rate within 3 months of being hospitalized for heart failure. Retrospective studies have shown benefit to using biomarkers such as BNP to guide inpatient heart failure management. Our own CCF retrospective study showed that decreasing NT-ProBNP by 23%, making patients fluid negative by more than 1.3L, and discharging patients with serum sodium above 135 reduces readmission rates significantly. The purpose of this study is to prospectively use the above mentioned goals in the treatment of heart failure in order to reduce heart failure readmission and mortality rates.

Interventions

  • OTHER Parameter Based Clinical Disposition

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2012-11
Est. Completion 2014-10

Sponsor

Cleveland Clinic Florida

7 total trials

What the Registry Record Tells You About NCT01726985

The ClinicalTrials.gov registry entry for NCT01726985 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cleveland Clinic Florida, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Parameter Based Clinical Disposition is the first listed.

NCT01726985 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01726985 about?

NCT01726985 is a clinical study titled "Model for Heart Failure ExAcerbation Reduction Trial". Heart failure is the leading cause of hospitalizations and readmissions in the United States and is a tremendous economic strain on our healthcare system. There is currently, based on national averages, a 30% readmission rate and 10% mortality rate within 3 months of being hospitalized for heart fai...

What is the current status of trial NCT01726985?

This trial is currently completed. The enrollment target is 230 participants. The study started on 2012-11. Estimated completion is 2014-10.

What interventions are being tested in trial NCT01726985?

The interventions under investigation include: Parameter Based Clinical Disposition (OTHER).

Who is sponsoring clinical trial NCT01726985?

This trial is sponsored by Cleveland Clinic Florida, which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.